|
Orthologous residues
|
|
MCL1 (human): T163‑p, MCL1 iso2 (human): T163‑p, MCL1 (mouse): T144‑p, MCL1 (rat): T143‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, phosphoamino acid analysis, phosphopeptide mapping
|
|
Disease tissue studied:
lymphoma, Burkitt's lymphoma
|
|
Relevant cell lines - cell types - tissues:
BL-41 (B lymphocyte), CHO (fibroblast) [EphB1 (human), transfection]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
hamster, human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
ERK2 (human)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
KINASE
|
ERK1 (human)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phorbol ester
|
|
|
|
increase
|
|
|
U0126
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
okadaic acid
|
|
|
|
no change compared to control
|
|
|
taxol
|
|
|
|
no change compared to control
|
|
|
